KERX - Keryx Biopharmaceuticals Inc.

chart.ashx?t=kerx&ta=1&p=d&s=l


Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of diabetes and cancer. The company's endocrine/renal products include Sulonex, a Phase III and Phase IV clinical stage product for the treatment of diabetic nephropathy; and Zerenex, a Phase II clinical stage product for the treatment of Hyperphosphatemia in patients with end-stage renal disease. Its oncology products include KRX-0401, a Phase II clinical stage product for the treatment of multiple forms of cancer; KRX-0402, a Phase II clinical stage product for the treatment of brain cancer; KRX-0601, a Phase II clinical stage product for the treatment of multiple forms of cancer; and KRX-0404, a pre-clinical stage product for the treatment of multiple forms of cancer. The company also develops neurology products, including KRX-0501, a pre-clinical stage product for the treatment of neurological disorders. In addition, it offers AccuminTM, a patent protected, diagnostic for the direct measurement of total and intact urinary albumin. It has strategic alliances with Alfa Wassermann S.p.A.; Collaborative Study Group; AEterna Zentaris, Inc.; Panion & BF Biotech, Inc.; Kyowa Hakko Kogyo Co., Ltd.; and AusAm Biotechnologies, Inc. for the manufacture and commercialization of its products. Keryx Biopharmaceuticals was founded in 1998. It was formerly known as Paramount Pharmaceuticals, Inc. and changed its name to Lakaro Biopharmaceuticals, Inc. in 1999. Later, the company changed its name to Keryx Biopharmaceuticals, Inc. in 2000. Keryx Biopharmaceuticals is based in New York, New York.